蛋白酶激活受体1 (PAR1) 表达有助于HPV相关的口腔癌预后
Yoshinori Fujita1,2, Yujiro Fukuda2, Fumiaki Sanuki1
1Department of Pathology, Kawasaki Medical University, 577 Matsushima, Kurashiki, Okayama, 701-0192, Japan.
蛋白酶激活受体-1 (PAR1) 表达影响人类乳头瘤病毒 (HPV) 相关的口腔癌预后和复发. 与HPV相关的口癌的PAR1阳性患者的预后较差,突出显示其在风险分层中的作用.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 人类乳头瘤病毒 (HPV) 相关的口腔癌 (OPC) 的预后是可变的,需要改进风险分层.
- 蛋白酶激活受体-1 (PAR1) 与致癌和瘤微环境有关.
- 含有α-arrestin域的蛋白3 (ARRDC3) 调节了PAR1的表达.
研究的目的:
- 评估PAR1,ARRDC3和瘤透淋巴细胞 (TILs) 在与HPV相关的OPC的预后价值.
- 为了比较这些标记物在下喉和子宫癌中作为对照.
主要方法:
- 在79个口腔喉癌,44个口腔下喉癌和42个子宫癌样本中对p16,ARRDC3和PAR1进行免疫组织化学分析.
- TIL成绩被分为低,中或高.
- 预测分析使用了风险分层的中位数切断值.
主要成果:
- p16阳性与OPC的预后改善相关.
- 帕尔1阴性状态与更好的疾病特异性存活率 (DSS) 和无疾病存活率 (DFS) 相关.
- 在p16阴性OPC中,ARRDC3阳性表明了更好的DSS预后;然而,在p16阳性OPC中,PAR1阳性预测了预后不佳,在p16阴性OPC中增加了35倍的复发风险.
结论:
- PAR1表达显著影响HPV相关OPC的预后和复发率.
- 在HPV相关的OPC中,PAR1作为风险分层的潜在预测生物标志物.
- 需要进一步研究ARRDC3在OPC预后中的作用.
更多相关视频
06:57Chromogenic In Situ Hybridization as a Tool for HPV-Related Head and Neck Cancer Diagnosis
Published on: June 14, 2019
07:43Four-color Fluorescence Immunohistochemistry of T-cell Subpopulations in Archival Formalin-fixed, Paraffin-embedded Human Oropharyngeal Squamous Cell Carcinoma Samples
Published on: July 29, 2017
相关概念视频
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Mechanisms of Retrovirus-induced Cancers
Mitogens and the Cell Cycle
